Nordic Life Sciences A/S: Financial statements 2023
CVR: 41727659
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
Nordic Life Sciences A/S (CVR 41727659) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -4,004,403 and a net result of DKK -3,272,239 compared with DKK -5,004,428 the year before. Equity in the 2023 report amounted to DKK -8,926,688.
- Gross Profit
- DKK -4,004,403
- Profit/Loss
- DKK -3,272,239
- Equity
- DKK -8,926,688
- Total Assets
- DKK 2,628,362
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Nordic Life Sciences A/S has published its annual report for 2022. Gross profit came to DKK -2,426,844, and the net result was DKK -5,004,428.
About Nordic Life Sciences A/S
Nordic Life Sciences A/S is a Danish company of the type Aktieselskab based in Søndersø, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named Real Canna Denmark A/S and Real Canna Denmark ApS. The management consists of Erik Sundt. The board consists of Erik Sundt and Pål Anders Nordvi. The company is owned by Erik Sundt. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -8,872,790 and a net result of DKK -9,299,716 compared with DKK -11,050,310 the year before. Equity in the 2025 report amounted to DKK -13,918,223.